Literature DB >> 8893989

Vaccines for bluetongue.

P K Murray1, B T Eaton.   

Abstract

Isolation of 8 serotypes of bluetongue virus (BTV) in Australia has led to widespread debate on how to prepare for an outbreak of bluetongue disease and the type of vaccine best suited to control bluetongue in Australia. This article describes the vaccine options under consideration by research workers and animal health administrators. The most widely discussed options are live attenuated virus, killed virus and virus-like particles (VLP) generated by recombinant baculoviruses. Attenuated virus vaccines are cheap and easy to produce and are administered in a single dose. They replicate in sheep without causing significant clinical effects and provide protection against challenge with virulent virus of the same serotype. The possibility that insects could acquire vaccine virus by feeding on vaccinated animals and transmit it to sheep or cattle cannot be eliminated. This poses a risk because attenuated viruses are teratogenic if ewes are infected in the first half of pregnancy. In addition, vaccine virus replication in insects and ruminants may lead to a reversion to virulence. Killed virus vaccines have been shown to be efficacious in small laboratory trials and cannot be transmitted to other animals in the field, but are significantly more expensive to produce than attenuated viruses and require at least 2 doses with adjuvant to elicit an immune response. More work is needed to properly assess their effectiveness and determine their cost of production. Recombinant VLP contain the 4 major structural proteins of BTV but no nucleic acid. VLP are relatively easy to isolate, but it is unlikely that the purification methods currently used in laboratories will be adapted for use commercially. Despite the enthusiasm of recent years, little commercial progress appears to have been made. Although scientific research in Australia and overseas has provided a number of options for development of bluetongue vaccines, the decisions on which to use in an outbreak are complex and will require, not only consideration of factors discussed here, but also agreement from industry and government.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8893989     DOI: 10.1111/j.1751-0813.1996.tb10036.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  4 in total

1.  Immune responses and protective efficacy of binary ethylenimine (BEI)-inactivated bluetongue virus vaccines in sheep.

Authors:  M A Ramakrishnan; A B Pandey; K P Singh; R Singh; S Nandi; M L Mehrotra
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

2.  Determinants of bluetongue virus virulence in murine models of disease.

Authors:  Marco Caporale; Rachael Wash; Attilio Pini; Giovanni Savini; Paola Franchi; Matthew Golder; Janet Patterson-Kane; Peter Mertens; Luigina Di Gialleonardo; Gisella Armillotta; Rossella Lelli; Paul Kellam; Massimo Palmarini
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

3.  Oncolytic bluetongue viruses: promise, progress, and perspectives.

Authors:  Joseph K-K Li
Journal:  Front Microbiol       Date:  2011-03-16       Impact factor: 5.640

4.  Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep.

Authors:  Coraline Bouet-Cararo; Vanessa Contreras; Agathe Caruso; Sokunthea Top; Marion Szelechowski; Corinne Bergeron; Cyril Viarouge; Alexandra Desprat; Anthony Relmy; Jean-Michel Guibert; Eric Dubois; Richard Thiery; Emmanuel Bréard; Stephane Bertagnoli; Jennifer Richardson; Gilles Foucras; Gilles Meyer; Isabelle Schwartz-Cornil; Stephan Zientara; Bernard Klonjkowski
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.